Dengjie Ouyang
Overview
Explore the profile of Dengjie Ouyang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Z, Zhao Y, Huang P, ZhaoyiWu , Ouyang D, Nyarko A, et al.
Sci Rep
. 2024 Dec;
14(1):32156.
PMID: 39741174
No abstract available.
2.
Li Z, Zhao Y, Huang P, Wu Z, Ouyang D, Nyarko A, et al.
Sci Rep
. 2024 Sep;
14(1):22263.
PMID: 39333272
ATAD2 (ATPase Family AAA Domain-Containing 2) is highly expressed across varies tumor types, yet its common roles in tumor progression and immune interaction remain unclear. We analyzed the expression and...
3.
Gao H, Ouyang D, Guan X, Xu J, Chen Q, Zeng L, et al.
BMC Cancer
. 2024 Jan;
24(1):50.
PMID: 38195475
Background: In the context of breast cancer (BC), the correlation between lymphocytes and clinical outcomes, along with treatment response, has garnered attention. Despite this, few investigations have delved into the...
4.
Ouyang D, Hong T, Fu M, Li Y, Zeng L, Chen Q, et al.
Breast Cancer Res
. 2023 Feb;
25(1):19.
PMID: 36765397
Background: Chemotherapy is an important strategy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+HER2-) breast cancer (BC), but this subtype has a low response rate to...
5.
Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, et al.
Ann Transl Med
. 2023 Jan;
10(24):1403.
PMID: 36660684
Background And Objective: Previous studies have demonstrated that the oncogene trophoblast cell surface antigen 2 () has great application prospects as a therapeutic target. However, few literature reviews have systematically...
6.
Wen Y, Ouyang D, Chen Q, Zeng L, Luo N, He H, et al.
Gland Surg
. 2022 Mar;
11(1):100-114.
PMID: 35242673
Background: Whether tumor mutation burden (TMB) correlated with improved survival outcomes or promotion of immunotherapies remained controversy in various malignancies. We aimed to explore the prognostic value of TMB and...
7.
Luo N, Wen Y, Zou Q, Ouyang D, Chen Q, Zeng L, et al.
Sci Rep
. 2022 Jan;
12(1):687.
PMID: 35027588
The current diagnostic technologies for assessing the axillary lymph node metastasis (ALNM) status accurately in breast cancer (BC) remain unsatisfactory. Here, we developed a diagnostic model for evaluating the ALNM...
8.
Cao Z, Jin Z, Zeng L, He H, Chen Q, Zou Q, et al.
Gland Surg
. 2021 Nov;
10(9):2766-2779.
PMID: 34733726
Background: The cumulative risk of distant recurrence of hormone receptor-positive (HR+) breast cancer in the past 20 years has ranged from 22% to 52% after 5 years of endo-therapy. The...
9.
Anwar M, Chen Q, Ouyang D, Wang S, Xie N, Ouyang Q, et al.
Clin Cancer Res
. 2021 Jun;
27(16):4634-4641.
PMID: 34112711
Purpose: Patients with HER2-positive (HER2) metastatic breast cancer (MBC) have poor prognoses. Pyrotinib has shown promising antitumor activity in MBC to improve progression-free survival (PFS). However, findings based on real-world...
10.
Chen Q, Ouyang D, Anwar M, Xie N, Wang S, Fan P, et al.
Front Oncol
. 2021 Mar;
11:661128.
PMID: 33747972
[This corrects the article DOI: 10.3389/fonc.2020.00811.].